ArticleEuropean journal of clinical pharmacology2020
Second-generation antipsychotics and pregnancy complications.
Article in European journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 6 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Antipsychotic drug use during pregnancy and neonatal outcomes: a systematic review and meta-analysis.Archives of women's mental health · 2026Pooled it
- Pooled it
- Effect of antipsychotic consumption during pregnancy on risk of gestational diabetes development: a systematic review and meta-analysis.Frontiers in psychiatry · 2025Pooled it
- Neonatal outcomes after in utero exposure to antipsychotics: a systematic review and meta-analysis.European journal of epidemiology · 2024Pooled it
- Is Antipsychotic Drug Use During Pregnancy Associated with Increased Malformation Rates and Worsening of Maternal and Infant Outcomes? A Systematic Review.Current neuropharmacology · 2024Pooled it
- Gestational Diabetes Mellitus in Europe: A Systematic Review and Meta-Analysis of Prevalence Studies.Frontiers in endocrinology · 2021Pooled it
- Outcomes of long-acting injectable antipsychotics use in pregnancy: A literature review.World journal of psychiatry · 2024Article
- Long-Acting Injectable Antipsychotic Treatment during Pregnancy: A Case Series.International journal of environmental research and public health · 2023Observational
- A prospective registry analysis of psychosocial and metabolic health between women with and without metabolic syndrome after a complicated pregnancy.BMC women's health · 2022Article
- Breastfeeding, pregnancy, medicines, neurodevelopment, and population databases: the information desert.International breastfeeding journal · 2022Review
- Neonatal morbidity after fetal exposure to antipsychotics: a national register-based study.BMJ open · 2022Article
- Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden.CNS drugs · 2022Article
- Antipsychotic Use in Pregnancy: Patient Mental Health Challenges, Teratogenicity, Pregnancy Complications, and Postnatal Risks.Neurology international · 2022Review
- Second-generation antipsychotic use during pregnancy and risk of congenital malformations.European journal of clinical pharmacology · 2021Article
- Second-generation antipsychotics and pregnancy complications: the impact of confounding by indication.European journal of clinical pharmacology · 2021Article
- Women with Schizophrenia over the Life Span: Health Promotion, Treatment and Outcomes.International journal of environmental research and public health · 2020Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo study if second-generation antipsychotic (S-GA) use during pregnancy is associated with an increased risk of pregnancy and neonatal complications.
methodsA population-based birth cohort study using national register data extracted from the "Drugs and Pregnancy" database in Finland, years 1996-2016. The sampling frame included 1,181,090 pregnant women and their singleton births. Women were categorized into three groups: exposed to S-GAs during pregnancy (n = 4225), exposed to first-generation antipsychotics (F-GAs) during pregnancy (n = 1576), and unexposed (no purchases of S-GAs or F-GAs during pregnancy, n = 21,125). Pregnancy outcomes in S-GA users were compared with those in the two comparison groups using multiple logistic regression models.
resultsComparing S-GA users with unexposed ones, the risk was increased for gestational diabetes (adjusted odds ratio, OR 1.43; 95% CI 1.25-1.65), cesarean section (OR 1.35; 95% CI 1.18-1.53), being born large for gestational age (LGA) (OR 1.57; 95% CI 1.14-2.16), and preterm birth (OR 1.29; 95% CI 1.03-1.62). The risk for these outcomes increased further with continuous S-GA use. Infants in the S-GA group were also more likely to suffer from neonatal complications. Comparing S-GA users with the F-GA group, the risk of cesarean section and LGA was higher (OR 1.25, 95% CI 1.03-1.51; and OR 1.89, 95% CI 1.20-2.99, respectively). Neonatal complications did not differ between the S-GA and F-GA groups.
conclusionsPrenatal exposure to S-GAs is associated with an increased risk of pregnancy complications related to impaired glucose metabolism. Neonatal problems are common and occur similarly in S-GA and F-GA users.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.